Bibliografia

 

1. Rogers DF. Physiology of Airway Mucus Secretion and Pathophysiology of Hypersecretion. Respir Care 2007; 52(9):1134-1146.

2. Fahy JV, Dickey BF. Airway Mucus Function and Dysfunction. N Engl J Med 2010; 363:2233-2247.

3. Rogers DF. Mucoactive Agents for Airway Mucus Hypersecretory Diseases. Respir Care 2007; 52(9):1176-1193.

4. Sadowska AM, Verbraecken J, Darquennes K et al. Role of Nacetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis. 2006; 1(4):425-434.

5. Pintucci JP, Corno S, Garotta M. Biofilms and infections of the upper respiratory tract. Eur Rev Med Pharmacol Sci. 2010; 14(8):683-690.

6. Pela R, Calcagni AM, Subiaco S et al. N-Acetylcysteine Reduces the Exacerbation Rate in Patients with Moderate to Severe COPD. Respiration 1999; 66:495-500.

7. Dekhuijzen PNR, van Beurden WJC. The role for N-acetylcysteine in the management of COPD. International Journal of COPD 2006; 1(2):99-106.

8. Gerrits CM, Herings RM, Leufkens HG et al. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J. 2003 May; 21(5):795-798.

9. Riassunto delle Caratteristiche del Prodotto Solmucol.

10. De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J 1997; 10: 1535-1541.

11. Demedts M, Behr J, Buhl R et al. High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis. N Engl J Med 2005; 353:2229-42.

12. Millea PJ. N-Acetylcysteine: Multiple Clinical Applications. Am Fam Physician. 2009; 80(3):265-269.